Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Devil is in the Details: CMS To Flesh Out Committee's Research Role

This article was originally published in RPM Report

Executive Summary

CMS plans to be more open about how the Medicare coverage advisory committee will score research priorities after comments from industry. Stakeholders know the process won't any easier after Election Day.

You may also be interested in...

Flourishing In the Sunshine: Disclosure as a new Commercial Advantage

Orthopedic device manufacturers are out ahead of the drug industry in adapting to new payment disclosure laws. One company, Stryker, has embraced the requirement wholeheartedly and may have found a way to make the listing a benefit to doctors and patients.

Medicare research priorities

The Medicare Evidence Development and Coverage Advisory Committee will convene April 30 in Baltimore, Md., to discuss priorities for research topics important to the Medicare program. The meeting is a follow-up to MedCAC's Oct. 22 meeting on the issue (1"The Gray Sheet" Nov. 12, 2007, p. 8)

The Value Proposition: Why Pharma Should Embrace Comparative Effectiveness

A greater investment in comparative effectiveness research appears inevitable, whether or not Congress creates a federally funded agency to conduct head-to-head trials. The Vytorin debacle is only the most recent reason why industry is wary. But there are steps pharma can take to prepare for the next big thing in health care policy. Despite Vytorin, Merck is one of the companies leading the way.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts